CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-2.85%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$1.76B
AUM Growth
+$1.76B
(+2.7%)
Cap. Flow
+$103M
Cap. Flow
% of AUM
5.87%
Top 10 Holdings %
Top 10 Hldgs %
56.83%
Holding
37
New
8
Increased
10
Reduced
6
Closed
4
Top Buys
| 1 |
Biogen
BIIB
|
$81.5M |
| 2 |
Alkermes
ALKS
|
$64.6M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$44.1M |
| 4 |
AbbVie
ABBV
|
$37.9M |
| 5 |
Novo Nordisk
NVO
|
$36.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$67.6M |
| 2 |
MDCO
Medicines Co
MDCO
|
$62M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$60M |
| 4 |
AGN
Allergan plc
AGN
|
$42.1M |
| 5 |
DaVita
DVA
|
$28.5M |
Sector Composition
| 1 | Healthcare | 97.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $168M | 8.85% | 1,000,000 -250,000 | -20% | -$42.1M |
|
2
Viatris
VTRS
$12.3B
| $168M | 8.84% | 8,500,000 -750,000 | -8% | -$14.8M |
|
3
Perrigo
PRGO
$3.27B
| $95M | 5% | 1,700,000 -300,000 | -15% | -$16.8M |
|
4
Brookdale Senior Living
BKD
$1.83B
| $94.8M | 4.98% | 12,500,000 | – | – |
|
|
5
DaVita
DVA
$9.85B
| $85.6M | 4.5% | 1,500,000 -500,000 | -25% | -$28.5M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $83.2M | 4.38% | 850,000 +450,000 | +113% | +$44.1M |
|
|
7
Biogen
BIIB
$19.4B
| $81.5M | 4.29% | +350,000 | New | +$81.5M |
|
8
Bristol-Myers Squibb
BMY
$96B
| $76.1M | 4% | 1,500,000 +500,000 | +50% | +$25.4M |
|
9
Universal Health Services
UHS
$11.6B
| $74.4M | 3.91% | 500,000 -150,000 | -23% | -$22.3M |
|
10
HCA Healthcare
HCA
$94.5B
| $72.3M | 3.8% | 600,000 | – | – |
|
11
Tenet Healthcare
THC
$16.3B
| $69.7M | 3.66% | 3,150,000 +650,000 | +26% | +$14.4M |
|
|
12
Alkermes
ALKS
$4.78B
| $68.3M | 3.59% | 3,500,000 +3,311,719 | +1,759% | +$64.6M |
|
13
Ascendis Pharma
ASND
$11.8B
| $62.6M | 3.29% | 650,000 | – | – |
|
14
Sarepta Therapeutics
SRPT
$1.78B
| $56.5M | 2.97% | 750,000 +250,000 | +50% | +$18.8M |
|
15
Nektar Therapeutics
NKTR
$568M
| $54.6M | 2.87% | 3,000,000 +500,000 | +20% | +$9.11M |
|
|
AMAG
16
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $50.7M | 2.67% | 4,390,000 +1,390,000 | +46% | +$16.1M |
|
|
MNTA
17
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $45.4M | 2.39% | 3,500,000 | – | – |
|
18
Atara Biotherapeutics
ATRA
$84.6M
| $41.7M | 2.19% | 2,950,000 +950,000 | +48% | +$13.4M |
|
|
19
AbbVie
ABBV
$372B
| $37.9M | 1.99% | +500,000 | New | +$37.9M |
|
20
Zymeworks
ZYME
$1.12B
| $37.2M | 1.96% | 1,500,000 -1,100,000 | -42% | -$27.3M |
|
|
21
Novo Nordisk
NVO
$251B
| $36.2M | 1.9% | +700,000 | New | +$36.2M |
|
22
United Therapeutics
UTHR
$13.8B
| $31.9M | 1.68% | 400,000 +32,471 | +9% | +$2.59M |
|
|
THOR
23
DELISTED
Synthorx, Inc. Common Stock
THOR
| $30.3M | 1.59% | 1,862,116 | – | – |
|
24
Myriad Genetics
MYGN
$593M
| $28.6M | 1.51% | +1,000,000 | New | +$28.6M |
|
25
Cyclerion Therapeutics
CYCN
$7.91M
| $27M | 1.42% | 2,227,052 +665,137 | +43% | +$8.06M |
|